Treating depression can be hard as each person is different on what works for them. Recently, a new study highlighted in The New York Times has shown that psilocybin is spurring brain activity for those who have depression.
Del Jolly, Co-Founder of UMBO, Unlimited Sciences and expert in functional mushrooms, the research at Unlimited Sciences collects real-world data on psychedelic use so that we can more quickly understand how to use these drugs safely and effectively for our health and overall wellbeing.
Jolly states, “With seemingly compounding events that test the mental wellness of everyone, society is looking for and needs options on how to combat mental illnesses. It just so happens that naturally occurring and statistically safe options such as psilocybin are breaking stigmas. Psilocybin containing mushrooms and synthetic psilocybin is proving to be beneficial in a host of ailments including treatment-resistant depression, end-of-life anxiety, cluster headaches and even eating disorders. While most of these studies take place in clinical trials, that is only how a fraction of people use psilocybin, mainly because of the draconian laws placed in the 70's.”
Unlimited Sciences, in collaboration with Johns Hopkins University,is currently working on their own study on how people use psilocybin in real world scenarios. With over 7000 participants they are finding a plethora of information on how psilocybin can be used to improve the lives of millions of people.
All of UMBO’s products are made proudly in the U.S.A and ship nationally across the country!
No comments:
Post a Comment